Exploring the Potential Drug Target ATP5MJ: A 6.8-kDa Proteolipid with N-Terminal Sequence Met-Leu-Gln (MLQ)

Target Name: ATP5MJ

NCBI ID: G9556

ATP5MJ

Exploring the Potential Drug Target ATP5MJ: A 6.8-kDa Proteolipid with N-Terminal Sequence Met-Leu-Gln (MLQ)

Introduction

ATP5MJ, a 6.8-kDa proteolipid with N-terminal sequence Met-Leu-Gln (MLQ), has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Its unique structure and biochemical properties make it an attractive candidate for drug development. In this article, we will explore the potential drug target ATP5MJ and its potential in disease treatment.

Structure and Properties of ATP5MJ

ATP5MJ is a type of lipid molecule that contains a phosphate group, a choline molecule, and a glycerol molecule. It has a molecular weight of 6.8 kDa and a calculated polar surface area of 鈥嬧??177.1 m虏/g. The N-terminal sequence of ATP5MJ is Met-Leu-Gln (MLQ), which consists of three amino acids: Met-Leu-Gln.

The MLQ sequence is important for ATP5MJ's unique properties and its potential as a drug target. The Met amino acid has a positively charged side and a negatively charged side, which can interact with other positively charged or negatively charged molecules. The Leu amino acid has a negatively charged side that can interact with negatively charged molecules. The Gln amino acid has a negatively charged side that can interact with negatively charged molecules. These interactions can alter the physical and chemical properties of ATP5MJ, including its solubility, stability, and interactions with other molecules.

Potential Drug Target

ATP5MJ has been identified as a potential drug target due to its unique structure and its potential to interact with other molecules. One of the main reasons for its potential as a drug target is its highiled potential, which means it has a large number of interactions with other molecules. This highiled potential can make it an attractive target for small molecules or antibodies that can modulate its activity.

In addition, ATP5MJ's MLQ sequence is highly conserved across various species, which indicates that it has been preserved for a long time and that it has a stable structure. This stability can make it more resistant to changes in the environment, such as those that may occur during drug treatment.

The Potential therapeutic benefits of ATP5MJ as a drug target are numerous. For example, it can be used to treat various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. It has been shown to have anti-inflammatory effects, which can be useful in treating neurodegenerative disorders and cardiovascular diseases.

Additionally, ATP5MJ has been shown to have neuroprotective effects, which can be useful in treating neurodegenerative disorders. Its MLQ sequence has been shown to have neuroprotective properties in animal models of neurodegenerative disorders, such as dopamine-induced neurotoxicity.

Despite the potential benefits of ATP5MJ as a drug target, its development as a therapeutic agent is still in its early stages. Further research is needed to determine its efficacy and safety in clinical trials.

Conclusion

In conclusion, ATP5MJ is a 6.8-kDa proteolipid with N-terminal sequence Met-Leu-Gln (MLQ) that has been identified as a potential drug target or biomarker in various diseases. Its unique structure and biochemical properties make it an attractive candidate for drug development. Further research is needed to determine its efficacy and safety in clinical trials. If its potential as a drug target is validated, it has the potential to treat a wide range of diseases and improve the quality of life for many patients.

Protein Name: ATP Synthase Membrane Subunit J

Functions: Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core and F(0) - containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation (Probable). Minor subunit required to maintain the ATP synthase population in the mitochondria (PubMed:24330338)

The "ATP5MJ Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP5MJ comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets